AAPS Workshop on Drug Transporters in ADME: From the Bench to the Bedside
April 16–18, 2018
Hyatt Regency Dulles
Dulles, Virginia
www.aaps.org/Transporters18
By Steven W. Louie, M.S., Bjoern Bauer, Ph.D., and Patrick T. Ronaldson, Ph.D.
The drug discovery and development processes have expanded beyond traditional ADME (absorption, distribution, metabolism, and elimination) transporters and small molecule therapeutics and into the multimodality space. To address this expansion as well as the role transporters and/or transport mechanisms play in drug disposition, drug-drug interactions, and drug toxicity, scientists must explore and examine new transporters and biomolecular therapeutics.
The April 16–18, 2018, AAPS Joint Workshop on Drug Transporters in ADME: From the Bench to the Bedside focuses on the next generation of transporters and transport mechanisms that may contribute to ADME properties in disease, drug discovery, and development.
Participants will:
- understand contributions of heteromeric transporters (ABCG5/G8, ABCD2, OSTa/b) to biliary excretion of cholesterol and disease states;
- explore intracellular mechanisms of lysosomal sequestration, large molecule transport (antibody, siRNA, antisense RNA);
- analyze current trends in transporter imaging, 3D culture models; and
- discuss in-silico approaches to predicting transporter substrate and inhibitor activity.
In addition, thought leaders from the International Transporter Consortium will discuss implications of recent white papers, and the Food and Drug Administration (FDA) and the European Medicines Agency will present their perspectives on the recently separated in vitro and in vivo transporter guidance.
Our keynote speaker, Per Artursson, Ph.D., is the head of the Drug Delivery research team in Dosage Form Design at the Department of Pharmacy, Uppsala University, Sweden. With more than 200 publications, Artursson is one of the world’s most cited pharmaceutical scientists.
Scientific posters will focus on the latest advances in transporters for participant collaboration. Additionally, corporate partners will be on hand to discuss their latest research and solutions.
Learn more about this workshop, and see the detailed agenda online.
Corporate partners will be available to support discussions around current challenges in transporters through small group discussions and exhibiting tabletops. To learn more, view the online program, or contact Business Development Manager Kate Hawley at HawleyK@aaps.org or +1.703.248.4785.
Development of Control Strategies for Oligonucleotides and Peptides: Regulatory and Industry Perspectives
April 11–12, 2018
Sheraton Silver Spring, Silver Spring, Md.
www.aaps.org/OligoPep2018
Those new to the field will receive a thorough grounding in the current Food and Drug Administration and European Medicines Agency perspectives, as well as practical problems faced in the industry.Experts will gain an understanding of how problems they face have been addressed by other companies and the current thoughts of regulators.
Goals and Objectives:
- Understanding common industry benchmarking practices.
- Learning existing regulatory and scientific considerations applicable to the development of suitable control strategies for oligonucleotide and
peptide drugs.
Who Should Attend?
Groups in the pharmaceutical industry involved in designing or implementing the control strategies for oligonucleotide and peptide drugs, including personnel in:
- product/process development,
- analytical development,
- quality control,
- stability,
- regulatory affairs,
- quality assurance, and
- project management.
The topic will be of direct and immediate relevance for companies focusing on these emerging modalities.
Sponsorship Opportunities
Sponsorship opportunities are available. To learn more, email Kate Hawley or call +1.703.248.4785.